In our study, PS downregulated hepatic FGFR4 expression, and inhibition of FGFR4 signaling has been reported to improve hepatic metabolism and is a promising option for the treatment of NAFLD and HCC [44–46]. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.